Promising results for orforglipron (oral non-peptide GLP-1 agonist; may be approved by 2026): 42% ▼hs-CRP, ▼IL-6 at higher doses, ▼ weight up to 15%, waist circumference by 13.6 cm. Oral admin more convenient c/w injection, better adherence, ▼ cost. www.drugnutritioninteractions.com#/news/news-d...